Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
162 participants
INTERVENTIONAL
2017-10-01
2019-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lumbar Puncture in Emergency Under Nitrous OXide
NCT03941990
Effects of Subanesthetic Concentrations of Nitrous Oxide - 1
NCT00000249
Use of 50% Nitrous Oxide / 50% Oxygen Premix in Primary Care Dental Centers
NCT00643838
Vapocoolant Spray for Reducing the Pain of Spinal Needle Insertion
NCT03175913
Effectiveness of Nitrous Oxide 50% for Reducing Pain and Distress Associated with Needle-stick in Children
NCT03342079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Thus, this study is designed to evaluate the analgesic effect of N2O on the pain induced during lumbar puncture.
Patients with scheduled lumbar puncture realized for diagnosis purposes will be randomized in 2 groups. One group will inhale N2O for the 5 minutes before the puncture and during the rest of the procedure. The second group will inhale compressed air during the same period of time. Neither the investigator realizing the lumbar puncture, nor the patient will know which type of gaz they are inhaling (double-blinding).
The maximal pain level that occurred during the procedure will be evaluated on a Numerical Rating Scale (NRS). NRS will also be used to evaluate the maximal anxiety induced by the procedure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nitrous oxide
will inhale experimental treatment (50% N2O - 50% O2)
Fixed 50:50 mixture of nitrous oxide and oxygen
Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
Placebo
will inhale medical air (22% O2 - 78% N2)
Placebo
inhale medical air (22% O2 - 78% N2)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fixed 50:50 mixture of nitrous oxide and oxygen
Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
Placebo
inhale medical air (22% O2 - 78% N2)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least 18
* no previous use of nitrous oxide
Exclusion Criteria
* Body Mass Index\>35
* Mini Mental State Examination \<24/30
* Temperature \>38°C
* Confusion
* Patient unable to communicate verbaly
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bordeaux
OTHER
Hospices Civils de Lyon
OTHER
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Université d'Auvergne
OTHER
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xavier MOISSET, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
CHU Clermont-Ferrand, Inserm, Neuro-Dol
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Clermont-Ferrand
Clermont-Ferrand, Auvergne, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-002750-37
Identifier Type: OTHER
Identifier Source: secondary_id
CHU-342
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.